Skip to main content

ArmonAir Digihaler FDA Approval History

Last updated by Judith Stewart, BPharm on May 2, 2024.

FDA Approved: Yes (Discontinued) (First approved February 20, 2020)
Brand name: ArmonAir Digihaler
Generic name: fluticasone propionate
Dosage form: Inhalation Powder for Oral Inhalation
Company: Teva Pharmaceuticals USA, Inc.
Treatment for: Asthma, Maintenance

ArmonAir Digihaler (fluticasone propionate) is an inhaled corticosteroid indicated for the maintenance treatment of asthma as prophylactic therapy in patients 12 years of age and older.

The digital inhalers from Teva Pharmaceuticals (ProAir Digihaler, ArmonAir Digihaler, and AirDuo Digihaler) will be discontinued from June 1, 2024. Asthma patients who use a Digihaler device should talk with their doctor about alternatives.

ArmonAir Digihaler contains a built-in electronic module which detects, records, and stores data on inhaler events, including peak inspiratory flow rate (L/min), for transmission to the mobile App where inhaler events are categorized.

ArmonAir Digihaler does not need to be connected to the app in order to use the medicine.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.